Search our Database of Scientific Publications and Authors

I’m looking for a

    327 results match your criteria Advances in Dermatology [Journal]

    1 OF 7

    Uncommon benign infantile vascular tumors.
    Adv Dermatol 2008 ;24:105-24
    Centre de Référence des Pathologies Neurovasculaires Malformatives, Site Trousseau, Service de Chirurgie Maxillo-Faciale et Chirurgie Plastique, AP-HP, Hôpital d'Enfants Armand Trousseau, Paris, France.
    Significant progress in the diagnosis of infantile vascular tumors has been achieved during the past 2 decades because of improvements in the recognition of clinical characteristics, radiologic features, and histopathologic analysis, as well as the discovery of important immunophenotypic markers such as GLUT-1. These recent advances make it possible to define more clearly the distinct clinical entities with their variable prognoses and to improve the management of lesions that, although histologically benign, infrequently may be lethal because of their invasive potential. Read More

    Cutaneous mosaicism: a molecular and clinical review.
    Adv Dermatol 2008 ;24:223-44
    Department of Dermatology and Pediatrics, Oregon Health & Science University, 3303 SW Bond Avenue, CH16D, Portland, OR 97239, USA.
    Physicians have long been intrigued by the distinct patterns created by epidermal nevi and other mosaic cutaneous disorders. Although many of the molecular mechanisms underlying these disorders remain unrevealed, with the release of the results of the Human Genome Project our knowledge is rapidly increasing. The underlying genetic defects for many of the X-linked and mosaic disorders have recently been identified. Read More

    Recent advances in acne vulgaris research: insights and clinical implications.
    Adv Dermatol 2008 ;24:197-209
    Department of Dermatology, University of California at San Francisco School of Medicine, 1701 Divisadero Street, 3rd Floor, San Francisco, CA 94115, USA.
    Understanding of acne vulgaris has taken major steps forward over the past few years. The renewed interest in the effect of dietary interventions on acne, the elucidation of the involvement of TLR and MMPs in acne pathogenesis, and a more detailed functional understanding of various treatment modalities at the molecular level are all promising indications that advances in therapeutics are sure to follow. Health utilities will serve not only as powerful outcome measures of treatment effects but also as clinical decision-making aids in everyday practice. Read More

    Update on the natural history and systemic treatment of psoriasis.
    Adv Dermatol 2008 ;24:171-96
    Florida State University College of Medicine/Dermatology Associates of Tallahassee, 1714 Mahan Center Boulevard, Tallahassee, FL 32308, USA.
    The onset of psoriatic disease and its associated comorbidities involves the interplay among a myriad of genetic and environmental risk factors. As we gain further insight into the immunopathogenesis of psoriasis, we hope it will provide the basis for the development of safer, more efficacious, and more durable therapeutics in the future. Given its enormous toll on patient health and quality of life, steps should be taken to prevent or decrease the risk for psoriasis-associated comorbidities through behavior modification and use of preventative health screenings and treatments. Read More

    Management of childhood psoriasis.
    Adv Dermatol 2008 ;24:125-69
    University of California, San Francisco, 1701 Divisadero Street, Box 0316, San Francisco, CA 94115, USA.
    Treating children with psoriasis represents one of the most rewarding yet constantly challenging endeavors in dermatology. These patients require time, energy, enthusiasm, empathy, and current, comprehensive knowledge of the unique clinical presentations in children and available therapies, including clinical action spectrum, mechanism of action, potential toxicity, and monitoring. Longitudinal trials examining the epidemiology and natural history of psoriasis, as well as the safety and efficacy of current and emerging treatments, are desperately needed in the pediatric population. Read More

    Toll-like receptors in skin.
    Adv Dermatol 2008 ;24:71-87
    University of California Los Angeles, Division of Dermatology, Center for Health Sciences, Room 52-121, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.
    TLRs have emerged as a major class of PRRs that are involved in detecting invading pathogens in the skin and initiating cutaneous immune responses. TLRs are expressed on many different cell types in the skin, including keratinocytes and Langerhans cells in the epidermis. Each TLR can recognize a different microbial component and there are differences among the TLR signaling pathways, which lead to distinct immune responses against a given pathogen. Read More

    Epigenetics of cutaneous melanoma.
    Adv Dermatol 2008 ;24:59-70
    Department of Pathology, University of Texas Southwestern Medical Center in Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
    Tumorigenesis is traditionally thought to be caused by the imbalance between oncogenes and tumor-suppressor genes. Epigenetics is a recently described phenomenon that uses an alternative mechanism to explain the transcriptional inactivation of tumor-suppressor genes predominantly by hypermethylation of the promoter regions. Hypermethylation of these regions has been described extensively in many neoplasms, including cutaneous melanoma. Read More

    Cutaneous squamous cell carcinoma.
    Adv Dermatol 2008 ;24:33-57
    Department of Dermatology, Mohs Micrographic Surgery and Cutaneous Oncology, Lahey Clinic, Harvard Medical School, 41 Mall Road, Burlington, MA 01805, USA.
    Cutaneous SCC is the second most common skin cancer among whites. Most cases of primary cutaneous SCC are induced by UV radiation. Chronic sun exposure is the major risk factor, and favored locations include the head and neck and other sun-exposed areas. Read More

    The nose: principles of surgical treatment.
    Adv Dermatol 2008 ;24:15-32
    Department of Dermatology, Mohs Micrographic Surgery and Cutaneous Oncology, Saint Louis University, 1402 South Grand Boulevard, Saint Louis, MO 63104, USA.
    Surgery on the nose is inseparable from the practice of dermatology. Extensive training and experience is required to account for the nose's unique role in determining individuality, its function as an airway, and its predilection for hosting aggressive tumors. This overview of anatomy and general surgical principles provides the novice with a foundation on which to build and the experienced practitioner a review of pertinent literature. Read More

    Emerging diseases in tropical dermatology.
    Adv Dermatol 2007 ;23:335-50
    Dermatology and Pathology, University of Colorado Health Sciences Center, P.O. Box 6510, Mail Stop F703, Aurora, CO 80045-0510, USA.
    All dermatologists worldwide should have at least passing familiarity with various tropical maladies that generate cutaneous manifestions. In addition to the standard infectious ailments associated with tropical environs, the authors have described herein five "emerging" illnesses that are gaining increasing attention for their capacity to cause human disease in those immigrating from, or traveling to, the tropical and subtropical world. Read More

    Dendritic cells and T cells in the regulation of cutaneous immunity.
    Adv Dermatol 2007 ;23:307-33
    Department of Dermatology, University of Münster, Von-Esmarch-Strasse 58, D-48149 Münster, Germany.
    DCs are a complex cell population in the skin consisting of epidermal LCs and dermal DCs, which differ in their anatomic location, antigen recognition, processing machinery, and migratory capacity. Cutaneous DCs (LCs as well as dermal DCs) function as sentinels that survey invading agents and transmit the information into immune responses by taking up exogenous antigens, migrating to draining LNs, and presenting the processed antigens to T cells resulting in T-cell differentiation and activation. Indeed, further studies are needed to clarify the specific contribution of each cutaneous DC subpopulation to antigen presentation and induction of cutaneous immune responses. Read More

    Hidradenitis suppurativa: an update.
    Adv Dermatol 2007 ;23:289-306
    Hospital of the University of Pennsylvania, Department of Dermatology, 3600 Spruce St., 2 Maloney, Philadelphia, PA 19104, USA.
    HS is a chronic, debilitating inflammatory dermatosis that is often refractory to treatment. Many medical therapies have been tried and some show efficacy. The introduction of new immunosuppressive medications has revolutionized the treatment of psoriasis in dermatology. Read More

    Bullous pemphigoid: physiopathology, clinical features and management.
    Adv Dermatol 2007 ;23:257-88
    Molecular and Cell Biology Laboratory, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via Monti di Creta 104, 00167 Rome, Italy.
    There has been a considerable progress in the understanding of the physiopathology of BP during the past 2 decades. The insights into the humoral and cellular immune response against BP180 and BP230 have increased significantly. Nevertheless, the factors underlying the initiation of the disease leading to a disruption of self-tolerance remain unclear. Read More

    Genetic immunodeficiency diseases.
    Adv Dermatol 2007 ;23:197-229
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
    The approach to the patient with genetic immunodeficiency is multidisciplinary, and requires close interaction between the primary care physician, immunologist, and other specialists. Dermatologists may play a key role in both the diagnosis of immunodeficiency based on recurrent infection or specific cutaneous abnormalities and in the management of cutaneous complications. The availability of bone marrow and stem cell transplantation has been life-saving for many affected children. Read More

    Emerging cutaneous infections in the premature neonate.
    Adv Dermatol 2007 ;23:177-95
    Section of Dermatology, Children's Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA.
    As the age of viability of premature neonates continues to decline, early recognition of emerging cutaneous infections will become increasingly important. Fungal and bacterial infections should always be included in the differential diagnosis of unusual-appearing skin lesions in the premature neonate since prompt evaluation and aggressive therapy is paramount in this high-risk population. Read More

    The efficacy and safety of amoxicillin, trimethoprim-sulfamethoxazole, and spironolactone for treatment-resistant acne vulgaris.
    Adv Dermatol 2007 ;23:155-63
    Department of Dermatology, Drexel University College of Medicine, Philadelphia, PA, USA.
    In situations where acne has proved resistant to other systemic agents or they are not indicated and isotretinoin is not desired by patients, the authors find amoxicillin, TMP-SMX, and spironolactone, alone or in combination, useful alternatives. In women who have acne, spironolactone can be used, and in patients who have sulfa allergy, amoxicillin can be used. It is important to continue alternate topical therapy along with these interventions to augment the improvement and to assist in the eventual discontinuance of oral medication. Read More

    Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium.
    Adv Dermatol 2007 ;23:131-54
    Yale Dermatopathology Service, Yale University School of Medicine, 15 York Street, LMP 5031, P.O. Box 208059, New Haven, CT 06520-8059, USA.
    NSF is a new and emerging disease. Significant investigative work to date has led to an unexpected suspect-gadolinium-containing contrast agents. Considerable additional work is now underway to formulate specific recommendations about the use of these agents in the population of patients who have renal disease. Read More

    Management of cutaneous melanoma: a public health and individual patient care perspective.
    Adv Dermatol 2007 ;23:81-98
    Dermatology Division, Memorial Sloan-Kettering Cancer Center, 160 East 53rd-St, New York, NY 10022, USA.
    The damaging impact of cutaneous melanoma on individuals and society is apparent. As dermatologists, we are in a unique position to help each patient on a personal level and make contributions with sweeping effects on a societal level. On an individual level, the successful care of each patient involves accurate and early diagnosis, proper education, sufficient biopsy, adequate surgical and medical managements, and long-term follow-up. Read More

    Genetic mutations involved in melanoma: a summary of our current understanding.
    Adv Dermatol 2007 ;23:61-79
    Department of Dermatology and Pathology, University of Colorado Health Sciences Center, P.O. Box 6510, Mail Stop F703, Aurora, CO 80045, USA.
    The biomolecular understanding of melanoma is in flux. The importance of high-penetrance genes involved in familial melanoma includes a significant number of mutations that directly lead to impairment of the checkpoints of the normal cell cycle. Furthermore, a greater understanding of the interaction between genetic factors and environmental factors, such as MC1R, CDKN2A, BRAF, and ultraviolet light, is emerging from landmark research. Read More

    Tumescent anesthesia: evolution and current uses.
    Adv Dermatol 2007 ;23:33-46
    Department of Dermatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA.
    The tumescent technique of local anesthesia is one of the great techniques developed in the last 20 years. It has dramatically changed the way clinicians perform many cutaneous surgical procedures. Those that use the technique are forever grateful for the insight that Dr. Read More

    The new World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas.
    Adv Dermatol 2006 ;22:259-77
    Yale University, 15 York Street, LMP 5031, New Haven, CT 06510, USA.
    The WHO-EORTC classification of cutaneous lymphomas is a good start to unifying nomenclature, a necessity before coherent consensus diagnoses can be made. There are three provisional diagnoses in this new classification that are not covered in detail in this review because they are rare diseases that still require further study for definitive classification. Much remains to be elucidated about cutaneous lymphomas, but understanding of the major entities within the new classification is an important first step in understanding these diverse diseases. Read More

    Photodynamic therapy.
    Adv Dermatol 2006 ;22:219-58
    Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
    ALA-PDT is a safe, well-tolerated, and effective treatment for many dermatologic conditions. Current data most strongly support its use in the treatment of actinic damage, but further investigation into alternative uses continues. Current efficacy is limited primarily by the depth of penetration of the photosensitizing agent and the activating light source. Read More

    The developmental biology of melanocytes and its application to understanding human congenital disorders of pigmentation.
    Adv Dermatol 2006 ;22:201-18
    In the past 15 years, a fruitful interplay between the description of mutations associated with human congenital disorders of pigmentation, the discovery of the molecular basis of murine coat color mutants, and the elucidation of determinants of melanocyte development from the neural crest has led to rapid advancement in the understanding of these disorders and the developmental biology underlying them. The insight gained about these human disorders from similar mouse models has facilitated progress that might not otherwise have occurred so rapidly. Clearly more work remains to be done, especially on the discovery of additional genes in humans that underlie the majority of WS2 cases not attributable to mutations in MITF. Read More

    Hitting the mark in hamartoma syndromes.
    Adv Dermatol 2006 ;22:181-200
    Department of Dermatology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA.
    The missed mark or hamartia underlying each hamartoma syndrome is a mutation in a tumor suppressor gene. This sets the stage for the development of frequent and early tumors in multiple organs. Loss of function of the tumor suppressor in neoplastic cells leads to dysregulation of signaling pathways and tumor growth. Read More

    More than just a bump: the hamartoma syndromes.
    Adv Dermatol 2006 ;22:157-80
    Department of Dermatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
    The hamartoma syndromes detailed in this review are just a few examples of the many genodermatoses now known to be associated with uncontrolled tumor proliferation secondary to mutations in tumor suppressor genes. Knowledge gained through the study of these syndromes has not only improved our understanding of patients afflicted with such conditions, but has also led to significant insight into the important role tumor suppressor genes play in preventing tumor formation and in carcinogenesis. As major strides continue to be made in the identification of causative mutations in the hamartoma syndromes, options for genetic testing will continue to expand. Read More

    Advances in the treatment of varicose veins: ambulatory phlebectomy, foam sclerotherapy, endovascular laser, and radiofrequency closure.
    Adv Dermatol 2006 ;22:139-56
    Dermatology, Weill Medical College, Cornell University, 772 Park Avenue, New York, NY 10021, USA.
    Dermatologists have played a key role in the advancement and development of new safe, noninvasive technologies that are utilized in the treatment of both cosmetic telangiectasias and larger varicose veins of medical significance. As presented in this article, major advances in sclerosing solutions, hook avulsion techniques, and endovascular RF and laser procedures have revolutionized the world of phlebology. This medical sector continues to evolve through its relevance to the ever-expanding aesthetic and aging population. Read More

    Current techniques in skin grafting.
    Adv Dermatol 2006 ;22:125-38
    MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 434, Houston, TX 77030, USA.
    A thorough knowledge of the techniques used in skin grafting is a necessity for successful soft-tissue reconstruction. Careful attention to detail and planning should ensure an excellent outcome. Current research in the fields of tissue engineering and skin substitutes continues to evolve with the ultimate goal being tissue-engineered skin that matches the quality of the autologous skin graft. Read More

    Systemic antifungal agents: an update of established and new therapies.
    Adv Dermatol 2006 ;22:101-24
    Department of Dermatology, Boston University School of Medicine, 609 Albany Street, Boston, MA 02118, USA.
    Terbinafine is the drug of choice for dermatophyte onychomycosis. Adjunct therapies, such as topical agents or surgical approaches, may improve outcomes in patients who have risk factors for incomplete response or recurrence. Despite many studies of newer antifungal agents for tinea capitis, griseofulvin (20 mg/kg/d) remains the gold standard. Read More

    Vulvar disease update.
    Adv Dermatol 2006 ;22:91-100
    Freeman-Cockerell Dermatopathology Laboratories, 2330 Butler Street, Suite 115, Dallas, TX 75235-9330, USA.
    In a busy dermatologic practice, it may be frustrating to encounter a vulvar disease patient, who must fully disrobe for examination. Further, the wet mounts, cultures, biopsies, and patient education required for treatment of vulvar disorders take up considerable time. However, most patients will respond to appropriate therapy, and can be very gratifying to treat. Read More

    Issues and advances in the management and pathogenesis of cutaneous lupus erythematosus.
    Adv Dermatol 2006 ;22:55-65
    University of California San Diego, 200 West Arbor Drive, MC 8420, San Diego, CA 92103, USA.
    Evidence-based therapy for cutaneous lupus is lacking. A new clinical assessment tool for cutaneous lupus, the CLASI score, will enable more standardized assessments of response to therapy. Anti-Ro autoantibodies are associated with photosensitive SLE and SCLE, and they play a role in cell survival following ultraviolet exposure. Read More

    Skin signs of systemic disease in childhood.
    Adv Dermatol 2006 ;22:1-30
    Department of Dermatology, University of California-San Francisco, 1701 Divisadero St., 3rd Floor, San Francisco, CA 94143-0316, USA.
    Several systemic disorders of childhood are characterized by cutaneous stigmata, and these skin signs can serve as important diagnostic clues. Many of the systemic illnesses that are seen in both the pediatric and adult populations often manifest in different ways with respect to their cutaneous features. Also, there are conditions that uniquely present in childhood, such as KD, HSP, acute hemmorhagic edema of infancy, and NOMID. Read More

    Antimicrobial peptides: effectors of innate immunity in the skin.
    Adv Dermatol 2005 ;21:357-74
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
    The ability of the cutaneous barrier to help defend the body against pathogens relies on both acquired and innate immune responses. Recently, a large body of research has suggested that a critical component of the innate immune response in the skin is 3 antimicrobial peptides: the cathelicidins, defensins, and dermcidins. These 3 classes of peptides have been shown to act as antimicrobials by directly inhibiting pathogen growth as well as potentiating other branches of the innate, humoral, and cell-mediated immune system. Read More

    1 OF 7